SUSTAIN 6 evaluated CV outcomes of subcutaneous semaglutide in 3,297 adults with type 2 diabetes and high cardiovascular risk over 104 weeks. Semaglutide reduced major adverse cardiovascular events (CV death, non-fatal MI, non-fatal stroke) by 26% vs placebo (HR 0.74). Established the CV benefit class label for semaglutide in T2D. NEJM 2016.
Drugs in this category
Related terms
- Semaglutide
- GLP-1 receptor agonist; active ingredient in Wegovy, Ozempic, and Rybelsus.